C71T
CANCELLED SECTION 71
06/12/2026
Back to search
Official data from USPTO
LUXCEPTAR
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
LUXCEPTAR
ST13
US500000079254181Class
5, 44
Filing
79254181
Registration
5917334
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
07/07/2026
Trademark type
Word
Nice classes
5, 44
Filing date
12/18/2018
Registration date
11/26/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/12/2026
Last transaction
07/07/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
98
Owner location
NL
Examiner
LATTUCA, FRANK J
Law office
L90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Kiadis Pharma Netherlands B.V.
Kiadis Pharma Intellectual Property B.V.
Representatives
No representative data.
Technical classification
Nice Classes
Class 5Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medical and veterinary preparations and articles for the immune modulation; pharmaceuticals and natural remedies namelynatural remedy preparations for the immune modulation; medicines for the immune modulation; pharmaceuticals for the immune modulation and for the prophylaxis of immune system related diseases and disorders; pharmaceutical preparationspreparations for immune modulation and for prophylaxis of immune system related diseases and disorders; pharmaceutical drugs namelypreparations for immune modulation and for prophylaxis of immune system related diseases and disorders; pharmaceutical implants namelyimplantable intravenously drug delivery devices sold filled with pharmaceutical preparations for the immune modulation; pharmaceutical preparations for activating cellular function; cellular function activating agents for medical purposes; clinical medical reagents; cultures of microorganisms for medical use; medical preparations namelypharmaceuticals and biological compounds to support the growth of stem cells; surgical implants comprised of living tissues grown from stem cells; medical diagnostic reagents; stem cells for research purposes; stem cells for medical purposes; reagents for blood grouping for medical purposes; anti-cancer drugs namely pharmaceuticals for the treatment of cancer; compounds namelyanti-cancer preparations for treating cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer
Class 44
Human healthcare services; medical services; pharmaceutical consultancy services; medical diagnostic testingmonitoringreporting services; medical treatment services namelymedical diagnosis and treatment for the immune modulation and prophylaxis of immune system related diseases and disorders; surgical treatment services; medical services relating to the removaltreatment and processing of stem cells; analysis of human serum for medical treatment; analysis of human tissues for medical treatment
Publications
History of USPTO decisions and trademark events.
25 publications found
CHLD
CHANGE OF OWNER RECEIVED FROM IB
08/09/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/19/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/10/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/03/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/16/2020
FIMP
FINAL DISPOSITION PROCESSED
03/16/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/26/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
11/26/2019
PUBO
PUBLISHED FOR OPPOSITION
09/10/2019
NPUB
NOTICE OF PUBLICATION
08/21/2019
ALIE
ASSIGNED TO LIE
08/08/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/29/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/26/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/26/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/26/2019
RFNT
REFUSAL PROCESSED BY IB
04/12/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/28/2019
RFRR
REFUSAL PROCESSED BY MPU
03/28/2019
MAFR
APPLICATION FILING RECEIPT MAILED
03/21/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/20/2019
CNRT
NON-FINAL ACTION WRITTEN
03/19/2019
DOCK
ASSIGNED TO EXAMINER
03/17/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/17/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/14/2019
Continuous trademark protection
Get notified about every new filing that threatens LUXCEPTAR or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.